Mateon Therapeutics Owners

Health Care & Life Sciences » Biotechnology | Mateon Therapeutics Inc.

Mateon Therapeutics Inc. | Ownership

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Perinvest (UK) Ltd.

210,213

0.51%

-1,000

0.25%

06/30/2017

Invesco Capital Management LLC

10,860

0.03%

09/05/2018

View Profile

Address	701 Gateway Boulevard South San Francisco California 94080 United States
Employees	-
Website	http://www.mateon.com
Updated	07/08/2019
Mateon Therapeutics, Inc. operates as a clinical stage biopharmaceutical company which develops small molecule injectable drugs for the treatment of cancer. The firm develops OXi4503 for the treatment of acute myeloid leukemia. The OXi4503 has dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.